Table 3.
The overview of studies based on the use of mesenchymal stem/stromal cells (MSCs) as a carrier for delivery of interferons to treat human tumors (in vitro and in vivo).
| Cancer | Interferon | Cell line/model | Results (Ref) |
|---|---|---|---|
| Liver cancer | IFN-α | HepG2 and Huh7 cell line | Inhibition of the proliferation and induction of G2/M phase arrest in HepG2 and Huh7 cell line by down-regulation of Notch signaling axis (81) |
| HCC tumor-bearing SCID mice | Inhibition of tumor growth in SCID mice (81) | ||
| Melanoma | IFN-α | B16F10 cell-bearing C57BL/6 mice | Attenuation of the growth of B16F10 melanoma cells, and thereby inhibition of lung metastasis in melanoma leading to the prolonged survival (83) |
| Plasmacytoma | IFN-α | Sp6 cell-bearing BALB/c mice | Induction of apoptosis of tumor cells, reduction in microvessel density, and ischemic necrosis in tumor-bearing mice (84) |
| Prostate cancer | IFN-β | PC-3 cell line | Inhibition of the proliferation of PC-3 cells in vitro (86) |
| PC-3 cell-bearing mice | Attenuation of PC-3 xenograft tumor weight and enhancing the mice survival (86) | ||
| TRAMP-C2 cell-bearing mice | Marked attenuation in tumor volume (87) | ||
| Liver cancer | IFN-β | HepG2 and Huh7 cell line | Inhibition of the proliferation and induction of G1 phase arrest in HepG2 and Huh7 cell line by downregulation of AKT/FOXO3a pathway (88) |
| HCC -bearing NOD/SCID mice | Suppression of HCC growth in vivo (88) | ||
| Squamous cell carcinoma | IFN-β | CAL27 cell line | Suppression of the proliferation of CAL27 cells in vitro and in vivo (94) |
| CAL27 cell-bearing BALB/c mice | |||
| Breast cancer | IFN-β | 4 T1 cell-bearing mice | Inhibition tumor growth by inhibition of STAT3 signaling resulted in diminished pulmonary and hepatic metastases (89) |
| Melanoma | IFN-β | LMeC cell line (canine) | Induction of tumor cell apoptosis by up-regulation of caspase-3 and Bak (90) |
| Melanoma | IFN-β | B16F10 cell-bearing C57BL/6 mice | Inhibition of the growth of melanoma leading to the prolonged survival by combine treatment of MSC-IFN-β and cisplatin (91) |
| Glioma | IFN-β | F98 cell-bearing rat | Hindrance of glioma growth by marked Batf3+ dendritic cells and CD8+ T-lymphocyte infiltration into tumor tissue (99) |
| Glioma | IFN-β | 9L glioma cell-bearing rat | Induction of tumor cell apoptosis, promotion of the antitumor cytokine secretion and CD4+ and CD8+ T-cell recruitment in intracranial glioma tissues (100) |
| Il-18 | |||
| Breast cancer | IFN-β | MDA-MB-231 cell line | Obstruction of the tumor growth through apoptosis (92) |
| Bronchioloalveolar carcinoma | IFN-β | H358 cell line | Inducing H358 cell apoptosis in vitro (93) |
| H358 cell-bearing SCID mice | Delayed tumor growth by stimulating apoptosis in vivo (93) | ||
| Bladder cancer | IFN-β | T24M cell-bearing mice | Pronounced suppression of tumor growth leading to the prolonged survival of mice (101) |
| Lung cancer | IFN-γ | H460 cell-bearing nude mice | Suppression of the growth and progression of lung carcinoma by caspase-3 activation (97) |
| Colon cancer | IFN-γ | colon26 cell-bearing nude mice | Inhibition of the proliferation of murine colon26 cell in vivo (98) |
IFN, interferon; FOXO3a, Forkhead box O3; HCC, hepatocellular carcinoma; STAT3, signal transducer and activator of transcription 3.